Ascentage Pharma Group International (AAPG) Income Statement
AAPG 2025 at a glance
Fiscal year ended December 31, 2025 · Chinese yuanAAPG revenue and net income
Where AAPG's revenue goes
2025Each bar shows an amount and its share of revenue. AAPG kept −216.5% of revenue as net income.
AAPG profit margins
AAPG growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −43.1% | +334.5% | +135.8% | — |
| Gross profit | −55.2% | +297.3% | +125.0% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AAPG income statement in Chinese yuan
| 2025 | 2024 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Revenue | CN¥558.5M | CN¥980.6M | CN¥14.5M | CN¥6.8M | CN¥6.3M | CN¥7.7M |
| Cost of revenue | CN¥131.7M | CN¥29.1M | CN¥2.1M | CN¥0 | CN¥0 | CN¥261,000 |
| Gross profit | CN¥426.7M | CN¥951.6M | CN¥12.4M | CN¥6.8M | CN¥6.3M | CN¥7.4M |
| Research & development | CN¥1.08B | CN¥947.2M | CN¥463.9M | CN¥249.6M | CN¥118.8M | CN¥102.7M |
| Sales, general & admin | CN¥599.9M | CN¥383.1M | CN¥98.9M | CN¥89.7M | CN¥13.4M | CN¥17.7M |
| Total operating expenses | CN¥1.61B | CN¥1.32B | CN¥595.1M | CN¥333.3M | CN¥137.0M | CN¥122.0M |
| Operating income | −CN¥1.18B | −CN¥369.7M | −CN¥582.7M | −CN¥345.4M | −CN¥130.7M | −CN¥114.6M |
| Interest income | CN¥82.1M | CN¥37.8M | — | — | — | — |
| Interest expense | CN¥52.6M | CN¥64.5M | CN¥4.3M | CN¥36.9M | CN¥57.9M | CN¥3.3M |
| Income before taxes | −CN¥1.20B | −CN¥395.3M | −CN¥1.48B | −CN¥360.4M | −CN¥120.1M | −CN¥107.8M |
| Income taxes | CN¥6.8M | CN¥10.4M | −CN¥1.6M | −CN¥1.6M | −CN¥1.6M | — |
| Net income | −CN¥1.21B | −CN¥405.4M | −CN¥1.48B | −CN¥345.3M | −CN¥118.5M | −CN¥107.8M |
| EBITDA | −CN¥1.09B | −CN¥237.6M | −CN¥1.47B | −CN¥326.3M | −CN¥49.7M | −CN¥116.2M |
| Gross margin | 76.4% | 97.0% | 85.6% | 100.0% | 100.0% | 96.6% |
| Operating margin | −211.1% | −37.7% | −4,014.9% | −5,074.8% | −2,064.9% | −1,495.0% |
| Net margin | −216.5% | −41.3% | −10,202.7% | −5,072.8% | −1,872.9% | −1,406.5% |
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥298.9M | CN¥334.1M | CN¥334.1M | CN¥233.7M | CN¥156.9M | CN¥156.9M | CN¥78.5M | CN¥823.7M | CN¥411.9M | CN¥79.3M | CN¥39.6M | CN¥142.7M |
| Cost of revenue | CN¥48.0M | CN¥68.7M | CN¥68.7M | CN¥21.6M | CN¥14.0M | CN¥14.0M | CN¥7.0M | CN¥15.1M | CN¥7.5M | CN¥12.4M | CN¥6.2M | CN¥18.2M |
| Gross profit | CN¥250.9M | CN¥265.4M | CN¥265.4M | CN¥212.0M | CN¥142.9M | CN¥142.9M | CN¥71.4M | CN¥808.7M | CN¥404.3M | CN¥66.9M | CN¥33.4M | CN¥124.5M |
| Research & development | CN¥678.8M | CN¥587.5M | CN¥587.5M | CN¥528.6M | CN¥503.2M | CN¥503.2M | CN¥251.6M | CN¥444.1M | CN¥222.0M | CN¥397.2M | CN¥198.6M | CN¥309.8M |
| Sales, general & admin | — | — | — | CN¥237.5M | CN¥206.5M | CN¥206.3M | CN¥103.1M | CN¥176.6M | CN¥88.3M | CN¥201.8M | CN¥100.8M | CN¥91.3M |
| Total operating expenses | CN¥994.8M | CN¥906.3M | CN¥906.3M | CN¥766.0M | CN¥709.7M | CN¥709.7M | CN¥354.8M | CN¥620.7M | CN¥310.4M | CN¥599.0M | CN¥299.5M | CN¥465.1M |
| Operating income | −CN¥744.0M | −CN¥640.9M | −CN¥640.9M | −CN¥554.0M | −CN¥566.8M | −CN¥566.8M | −CN¥283.4M | CN¥188.0M | CN¥94.0M | −CN¥532.1M | −CN¥266.0M | −CN¥340.6M |
| Interest expense | CN¥26.5M | CN¥25.8M | CN¥25.8M | — | — | — | — | CN¥28.0M | — | CN¥20.3M | — | CN¥75.8M |
| Income before taxes | −CN¥794.5M | −CN¥638.7M | −CN¥638.7M | −CN¥585.3M | −CN¥558.1M | −CN¥558.1M | −CN¥279.1M | CN¥162.9M | CN¥81.4M | −CN¥533.3M | −CN¥266.6M | −CN¥399.6M |
| Income taxes | CN¥13.5M | CN¥1.4M | CN¥1.4M | CN¥5.5M | CN¥10.4M | CN¥10.4M | CN¥5.2M | CN¥69,000 | CN¥34,500 | −CN¥9.9M | −CN¥4.9M | CN¥2.7M |
| Net income | −CN¥807.7M | −CN¥640.0M | −CN¥640.0M | −CN¥590.8M | −CN¥568.4M | −CN¥568.4M | −CN¥284.2M | CN¥163.0M | CN¥81.5M | −CN¥523.3M | −CN¥261.6M | −CN¥402.4M |
| EBITDA | −CN¥701.1M | −CN¥599.0M | −CN¥599.0M | −CN¥510.0M | −CN¥522.0M | −CN¥528.5M | −CN¥264.2M | CN¥229.6M | CN¥114.8M | −CN¥492.7M | −CN¥246.3M | −CN¥250.9M |
| Gross margin | 83.9% | 79.4% | 79.4% | 90.7% | 91.1% | 91.1% | 91.1% | 98.2% | 98.2% | 84.4% | 84.4% | 87.3% |
| Operating margin | −248.9% | −191.8% | −191.8% | −237.1% | −361.2% | −361.2% | −361.2% | 22.8% | 22.8% | −671.1% | −671.1% | −238.7% |
| Net margin | −270.2% | −191.5% | −191.5% | −252.8% | −362.3% | −362.3% | −362.3% | 19.8% | 19.8% | −660.0% | −660.0% | −282.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in Chinese yuan as reported in AAPG's financial statements (latest annual report filed April 29, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AAPG financial results
In fiscal year 2025 (ended December 31, 2025), Ascentage Pharma Group International reported revenue of CN¥558.5 million, down 43.1% from the year before. It had a net loss of CN¥1.2 billion, a net profit margin of −216.5%. Over five years revenue grew at an average rate of 135.8% a year. Figures are in Chinese yuan, the currency of its financial statements.
See the AAPG stock overview for the latest quote and news, or the AAPG chart for price history and technical indicators.
AAPG income statement FAQ
What is Ascentage Pharma Group International's annual revenue?
Ascentage Pharma Group International reported total revenue of CN¥558.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 43.1% from CN¥980.6 million the previous year.
Is Ascentage Pharma Group International profitable?
No. Ascentage Pharma Group International reported a net loss of CN¥1.2 billion in fiscal 2025, a net profit margin of −216.5%; its operating margin was −211.1%.
What is Ascentage Pharma Group International's gross margin?
Ascentage Pharma Group International's gross margin was 76.4% in fiscal 2025: for every $100 of revenue, Ascentage Pharma Group International kept $76 after the direct cost of its products and services.
How much does Ascentage Pharma Group International spend on research and development?
Ascentage Pharma Group International spent CN¥1.1 billion on research and development in fiscal 2025, 194.0% of revenue.
How fast is Ascentage Pharma Group International growing?
Revenue grew 135.8% a year on average over the last five fiscal years, from CN¥7.7 million to CN¥558.5 million.
When does Ascentage Pharma Group International's fiscal year end?
Ascentage Pharma Group International's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 29, 2026.